Ciloxan Related Published Studies
Well-designed clinical trials related to Ciloxan (Ciprofloxacin Ophthalmic)
A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. [2009.07]
Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial. [2008.03]
Pharmacokinetics of topically applied ciprofloxacin in equine tears. [2007.11]
Comparison of topical gatifloxacin 0.3% and ciprofloxacin 0.3% for the treatment of bacterial keratitis. [2006.02]
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. [2005.03]
Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. [2004.04]
Effect of topical dexamethasone and ciprofloxacin on bacterial flora of healthy conjunctiva. [2004.03]
Comparison of topical lomefloxacin 0.3 per cent versus topical ciprofloxacin 0.3 per cent for the treatment of presumed bacterial corneal ulcers. [2004.03]
An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoemulsification. [2004.02]
Corneal penetration of levofloxacin into the human aqueous humour: a comparison with ciprofloxacin. [2003.12]
Intraocular ciprofloxacin levels after oral administration in silicone oil-filled eyes. [2003.02]
Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery: randomized controlled clinical trial. [2001.12]
Penetration of ofloxacin and ciprofloxacin into the aqueous humor of eyes with functioning filtering blebs: a randomized trial. [2001.09]
Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis. [2001.03]
Epithelial healing rates with topical ciprofloxacin, ofloxacin, and ofloxacin with artificial tears after photorefractive keratectomy. [2000.05]
Penetration of ofloxacin and ciprofloxacin in aqueous humor after topical administration. [1999.06]
Comparison of aqueous humour and vitreous humour levels of two 0.3% ciprofloxacin eyedrops. [1998.12]
Antimicrobial effect of ciprofloxacin, povidone-iodine, and gentamicin in the decontamination of human donor globes. [1998.01]
A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. [1997.08]
Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. [1996.11]
Ciprofloxacin ophthalmic solution in the treatment of conjunctivitis and blepharitis: a comparison with fusidic acid. [1996.10]
Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions. [1996.07]
Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. [1995.04]
Corneal tissue levels of topically applied ciprofloxacin. [1995.03]
Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. [1994.01]
Evaluation of efficacy and safety of ciprofloxacin ophthalmic solution versus chloramphenicol. [1993.04]
Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. [1991.10]
Well-designed clinical trials possibly related to Ciloxan (Ciprofloxacin Ophthalmic)
Topical diclofenac versus dexamethasone after strabismus surgery: A double-blind randomized clinical trial of anti-inflammatory effect and ocular hypertensive response. [2007.07]
Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. [2006.06]
Ocular bioerodible minitablets as strategy for the management of microbial keratitis. [2004.09]
Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. [2003.09]
The use of otic powder in the treatment of acute external otitis. [2002.05]
Other research related to Ciloxan (Ciprofloxacin Ophthalmic)
Ciprofloxacin liposomes as vesicular reservoirs for ocular delivery: formulation, optimization, and in vitro characterization. [2009.05]
Ophthalmic controlled release in situ gelling systems for ciprofloxacin based on polymeric carriers. [2009.04]
Transcorneal iontophoresis for delivery of ciprofloxacin hydrochloride. [2008.08]
Ocular poloxamer-based ciprofloxacin hydrochloride in situ forming gels. [2008.07]
In situ ophthalmic gel of ciprofloxacin hydrochloride for once a day sustained delivery. [2008.04]
[Conjunctival bacterial flora after topical use of ciprofloxacin and gatifloxacin in cataract surgery] [2008.03]
Pharmacokinetics of topically applied ciprofloxacin in tears of mesocephalic and brachycephalic dogs. [2008.01]
A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis. [2007.06]
Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits. [2007]
A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model. [2006.01]
Variability in the content of Indian generic ciprofloxacin eye drops. [2005.09]
Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. [2005.05]
Release of ciprofloxacin from chondroitin 6-sulfate-graft-poloxamer hydrogel in vitro for ophthalmic drug delivery. [2005.05]
Effectiveness of topical taurolidine versus ciprofloxacin, ofloxacin, and fortified cefazolin in a rabbit Staphylococcus aureus keratitis model. [2005.03]
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction. [2005.02]
Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. [2005.02]
Comparative efficacy of topical gatifloxacin with ciprofloxacin, amikacin, and clarithromycin in the treatment of experimental Mycobacterium chelonae keratitis. [2004.08]
A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. [2004.08]
A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. [2004.08]
Multicomposite ultrathin capsules for sustained ocular delivery of ciprofloxacin hydrochloride. [2004.07.16]
Release of ciprofloxacin from poloxamer-graft-hyaluronic acid hydrogels in vitro. [2003.07.09]
Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. [2003.07]
Development of an ophthalmic formulation containing ciprofloxacin-hydroxypropyl-b-cyclodextrin complex. [2003.06]
Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: in vitro and in vivo studies. [2003.02]
Penetration of oral and topical ciprofloxacin into the aqueous humour. [2003.02]
Preparation of in situ-forming ophthalmic gels of ciprofloxacin hydrochloride for the treatment of bacterial conjunctivitis: in vitro and in vivo studies. [2003.02]
[Clinical efficacy of ciprofloxacin 0.3%9 (Ciloxan) in the treatment of bacterial infections of the external eye segment] [2003]
Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis. [2001.11]
Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium. [2001.10]
Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva. [2000.11]
Aqueous humour levels of topically applied ciprofloxacin and ofloxacin in the same subjects. [1999.10]
Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. [1999.10]
Antibacterial activity of the white precipitate formed on the corneal surface after treatment with ciprofloxacin ophthalmic solution. [1999.09]
Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. [1999.08]
Penetration of topical ciprofloxacin by presoaked medicated soft contact lenses. [1999.07]
Ciprofloxacin-resistant Pseudomonas keratitis. [1999.07]
Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes. [1999.02]
Effectiveness of ciprofloxacin-polystyrene sulfonate (PSS), ciprofloxacin and ofloxacin in a Staphylococcus keratitis model. [1998.08]
Topical ciprofloxacin for treating nontuberculous mycobacterial keratitis. [1998.02]
Penetration of topically applied ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor of the uninflamed human eye. [1997.08]
[Results of therapy using Ciloxan-Alcon in clinical practice] [1997.05]
Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. [1997.05]
Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humours of patients by different topical application modes. [1997]
Absorption of topically administered ciprofloxacin, ofloxacin and gentamicin in the inflamed rabbit eye. [1996]
Clinical evaluation of ciprofloxacin ophthalmic solution in the treatment of refractory bacterial keratitis. [1995.12]
Topical ciprofloxacin for otorrhea after tympanostomy tube placement. [1995.08]
Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration. [1995.06]
Tear concentrations of topically applied ciprofloxacin. [1994.11]
Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. [1994.11]
Comparative efficacy of topical ciprofloxacin for treating Mycobacterium fortuitum and Mycobacterium chelonae keratitis in an animal model. [1994.05.15]
Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. [1994.05]
Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. [1994.03]
Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. [1993.11]
0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. The Ciprofloxacin Ointment/Bacterial Keratitis Study Group. [1993.09]
Deposition of ciprofloxacin, prednisolone phosphate, and prednisolone acetate in SeeQuence disposable contact lenses. [1993.07]
Prednisolone acetate or prednisolone phosphate concurrently administered with ciprofloxacin for the therapy of experimental Pseudomonas aeruginosa keratitis. [1993.05]
Ciprofloxacin ointment versus ciprofloxacin drops for therapy of experimental Pseudomonas keratitis. [1993.03]
Methicillin-resistant Staphylococcus aureus keratitis in the rabbit: therapy with ciprofloxacin, vancomycin and cefazolin. [1992.11]
Mycobacterium fortuitum keratitis. A comparison of topical ciprofloxacin and amikacin in an animal model. [1992.11]
Ciprofloxacin-resistant bacterial keratitis. [1992.09.15]
Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. [1988.10]
Other possibly related research studies
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. [2005.05]
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. [2004.05]
Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea. [2003.10.06]
Lomefloxacin is an effective treatment of experimental bacterial keratitis. [2001.04]
Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. [2000.03]
Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). [2005.11]
Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. [2005.11]
An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. [2005.11]
|
